Join the Avacincaptad Pegol group to help and get support from people like you.
Avacincaptad Pegol News
Monthly News Roundup - February 2025
FDA Updates Izervay Label to Lengthen Treatment Duration for Geographic Atrophy Izervay (avacincaptad pegol) from Astellas is now FDA-approved without a limitation on duration of dosing, allowing...
U.S. FDA Approves Expanded Label for Astellas' Izervay (avacincaptad pegol intravitreal solution) for Geographic Atrophy
TOKYO, Feb. 12, 2025 /PRNewswire/ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S....
FDA Approves Izervay (avacincaptad pegol) Intravitreal Solution for the Treatment for Geographic Atrophy
TOKYO, Aug. 5, 2023 /PRNewswire/ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the U.S. Food and Drug Administration (FDA) approved Izervay™ (...